✦ LIBER ✦

Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung

✍ Scribed by Anderson, Gerald; Clavel, Michel; Smyth, John; Giaccone, Guiseppe; Gracia, Marco; Planting, Andre S.; Dalesio, Otilia; Kirkpatrick, Anne; McVie, Gordon

Book ID: 122448635
Publisher: Elsevier Science
Year: 1989
Weight: 198 KB
Volume: 25
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(89)90140-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical study of 9-hydroxy-2N-m

Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule

✍ Dodion, P.; Rozencweig, M.; Nicaise, C.; Piccart, M.; Cumps, E.; Crespeigne, N.; 📂 Article 📅 1982 🏛 Elsevier Science ⚖ 382 KB

Covalent binding of the antitumor agent

Covalent binding of the antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly a in vitro

✍ Bernard Dugue; Claude Paoletti; Bernard Meunier 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 366 KB

Phase II study of high-dose megestrol ac

Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma

✍ Veenhof, C.H.N.; van der Burg, M.E.L.; Nooy, M.; Aalders, J.G.; Pecorelli, S.; O 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 274 KB

Phase II study of viscum fraxini-2 in pa

Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma

✍ Mabed, M; El-Helw, L; Shamaa, S 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 144 KB

Phase II study of recombinant beta inter

Phase II study of recombinant beta interferon in patients with advanced non-small-cell lung carcinoma

✍ Ettinger, David S. ;Harwood, Kerry 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

Eighteen patients with advanced non-smallcell lung cancer (NSCLC) received recombinant beta interferon, 90 million units three times weekly. No complete or partial responses were seen. Five patients had stable disease for several months. Most patients experienced some toxicity, most commonly fever a

Phase II study of Temodal in the treatme

Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma

✍ Anthony T. C. Chan; Thomas W. T. Leung; Wing H. Kwan; Tony S. K. Mok; Winnie Yeo 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 246 KB